全文获取类型
收费全文 | 183079篇 |
免费 | 17491篇 |
国内免费 | 8065篇 |
专业分类
耳鼻咽喉 | 2419篇 |
儿科学 | 3988篇 |
妇产科学 | 2478篇 |
基础医学 | 31960篇 |
口腔科学 | 5762篇 |
临床医学 | 14915篇 |
内科学 | 23545篇 |
皮肤病学 | 4517篇 |
神经病学 | 9997篇 |
特种医学 | 4448篇 |
外国民族医学 | 118篇 |
外科学 | 15710篇 |
综合类 | 29039篇 |
现状与发展 | 48篇 |
一般理论 | 5篇 |
预防医学 | 7088篇 |
眼科学 | 3611篇 |
药学 | 14974篇 |
85篇 | |
中国医学 | 6836篇 |
肿瘤学 | 27092篇 |
出版年
2024年 | 180篇 |
2023年 | 2685篇 |
2022年 | 3563篇 |
2021年 | 6502篇 |
2020年 | 6243篇 |
2019年 | 5864篇 |
2018年 | 6097篇 |
2017年 | 6450篇 |
2016年 | 6775篇 |
2015年 | 7596篇 |
2014年 | 11465篇 |
2013年 | 12769篇 |
2012年 | 10992篇 |
2011年 | 12097篇 |
2010年 | 9885篇 |
2009年 | 9404篇 |
2008年 | 9872篇 |
2007年 | 9938篇 |
2006年 | 9005篇 |
2005年 | 8152篇 |
2004年 | 7199篇 |
2003年 | 6198篇 |
2002年 | 5053篇 |
2001年 | 4332篇 |
2000年 | 3561篇 |
1999年 | 3109篇 |
1998年 | 2532篇 |
1997年 | 2493篇 |
1996年 | 2143篇 |
1995年 | 2166篇 |
1994年 | 1925篇 |
1993年 | 1590篇 |
1992年 | 1309篇 |
1991年 | 1227篇 |
1990年 | 954篇 |
1989年 | 895篇 |
1988年 | 837篇 |
1987年 | 688篇 |
1986年 | 618篇 |
1985年 | 798篇 |
1984年 | 713篇 |
1983年 | 498篇 |
1982年 | 533篇 |
1981年 | 420篇 |
1980年 | 357篇 |
1979年 | 277篇 |
1978年 | 186篇 |
1977年 | 153篇 |
1976年 | 122篇 |
1975年 | 47篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
91.
目的:探讨中性粒细胞/淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)对初治前弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)患者预后的意义。方法:回顾性分析2010年1月至2019年10月,新疆医科大学附属肿瘤医院收治的165例初治DLBCL患者,确定了NLR(>2.77)在预后预测中的最佳临界值,采用Log-rank检验和Cox回归模型进行分析,评价治疗前NLR对无进展生存期(progression free survival time,PFS)和总生存期(overall survival rate,OS)的影响。结果:在入选的165例患者中,有67例患者治疗前NLR升高(>2.77),NLR升高与PFS和OS较短的患者明显相关(P<0.001和P=0.003)。多变量分析进一步表明,NLR>2.77是PFS的独立预测因子。结论:治疗前NLR升高提示DLBCL患者预后不良。 相似文献
92.
93.
94.
Mariano E. Menendez Suleiman Y. Sudah Patrick J. Denard 《Seminars in Arthroplasty》2022,32(3):644-649
BackgroundThe growing enthusiasm for the use of reverse shoulder arthroplasty (RSA) in the treatment of primary glenohumeral osteoarthritis (GHOA) with an intact rotator cuff is based on data derived from single-center studies with limited generalizability and follow-up. This study compared patient-reported outcomes (PROs) between RSA and total shoulder arthroplasty (TSA) for the treatment of primary GHOA with up to 5-year follow-up and examined temporal trends in the treatment of GHOA between 2012 and 2021.MethodsA retrospective review was performed on patients with primary GHOA undergoing primary arthroplasty surgery from the Surgical Outcomes System global registry between 2012 and 2021. PROs including the American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE) score, and visual analog scale (VAS) for pain were compared between RSA and TSA at 1, 2, and 5 years postoperatively.ResultsA total of 4451 patients were included, with 2693 (60.5%) undergoing TSA and 1758 (39.5%) undergoing RSA. Both RSA and TSA provided clinically excellent outcomes at 1 year postoperatively (ASES: 80.8 ± 17.9 vs. 85.9 ± 15.2, respectively; SANE: 74.8 ± 24.7 vs. 79.5 ± 22.9; VAS pain: 1.3 ± 2.0 vs. 1.1 ± 1.7; all P < .05) that were maintained at 2 years (ASES: 81.3 ± 19.3 vs. 87.3 ± 14.9; SANE: 74.8 ± 26.2 vs. 79.7 ± 24.7; VAS pain: 1.3 ± 2.1 vs. 1.0 ± 1.6; all P < .05) and 5 years (ASES: 81.7 ± 16.5 vs. 86.9 ± 15.3; SANE: 71.6 ± 28.5 vs. 78.2 ± 25.9; VAS pain: 1.0 ± 1.7 vs. 1.0 ± 1.7; all P < .05), with statistical significance favoring TSA. After controlling for age and sex, there was an adjusted difference of 4.5 units in the ASES score favoring TSA (P = .005) at 5 years postoperatively but no differences in adjusted SANE (P = .745) and VAS pain (P = .332) scores. The use of RSA for GHOA grew considerably over time, from representing only 17% of all replacements performed for GHOA in 2012 to nearly half (47%) in 2021 (P < .001).ConclusionRSA as a treatment for GHOA with an intact rotator cuff seems to yield PROs that are largely clinically equivalent to TSA extending to 5 years postoperatively. The observed statistical significance favoring TSA appears to be of marginal clinical benefit based on established minimal clinically important differences and may be a result of the large sample size. Further research using more granular clinical data and examining differences in range of motion and complications is warranted as it may change the value analysis. 相似文献
95.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献
96.
Xiaoke Zhu Yu Heng Jian Zhou Hanqing Lin Liang Zhou Ming Zhang Pengyu Cao Lei Tao 《International journal of cancer. Journal international du cancer》2023,153(1):94-102
A high risk of developing second primary malignancy (SPM) has been reported among head and neck cancer patients. Here, we aimed to statistically quantify the impact of SPM development on the survival of head and neck cancer patients. Our study was conducted using the Surveillance, Epidemiology and End Results database to collect the data of 48 316 patients who received curative surgical resection for initial primary head and neck squamous cell carcinoma (IP-HNSCC) in 1975 to 2019. SPM diagnosis was treated as a time-varying covariate and multivariable Cox regression analysis was conducted to estimate the association between SPM development and survival, overall or by the subsite of IP-HNSCC. Of the included patients, 11 238 patients (23.3%) developed SPM during the follow-up period. A significant reduction in survival was observed among patients with SPM (hazard ratio [HR] for overall survival, 3.30; 95% confidence interval [CI]: 3.20-3.41). The impact of SPM development on reduced survival was more significant in patients with localized IP-HNSCC vs regional IP-HNSCC (HROS, 3.41; 95% CI: 3.24-3.6 vs HROS, 3.18; 95% CI: 3.05-3.31; P for interaction <.001). The survival impact of SPM development was more evident in younger patients than in older patients. SPM in lung and bronchus was associated with the most pronounced reduction in survival, overall and across all subsites of HNSCC. Our results indicated that SPM development led to a significant reduction in survival. A greater survival benefit may be achieved through intensive surveillance for SPM in lung and bronchus targeting younger patients and those with localized HNSCC. 相似文献
97.
《The Journal of thoracic and cardiovascular surgery》2023,165(2):750-760.e5
ObjectivesThe reduction of postoperative acute kidney injury in patients undergoing cardiopulmonary bypass surgery using an oxygen delivery-guided perfusion strategy (oxygen delivery strategy) for cardiopulmonary bypass management compared with a fixed flow perfusion (conventional strategy) remains controversial. The purpose of this study was to determine whether a oxygen delivery strategy would reduce the incidence of postoperative acute kidney injury in patients undergoing cardiopulmonary bypass surgery.MethodsWe randomly enrolled 300 patients undergoing cardiopulmonary bypass surgery. Patients were randomly assigned to a oxygen delivery strategy (maintaining a oxygen delivery index value >300 mL/min/m2 through pump flow adjustments during cardiopulmonary bypass) or a conventional strategy (a target pump flow was determined on the basis of the body surface area). The primary end point was the development of acute kidney injury. Secondary end points were the red blood cell transfusion rate and number of red blood cell units, intubation time, postoperative length of stay in the intensive care unit and the hospital, predischarge estimated glomerular filtration rate, and hospital mortality.ResultsAcute kidney injury occurred in 20 patients (14.6%) receiving the oxygen delivery strategy and in 42 patients (30.4%) receiving the conventional strategy (relative risk, 0.48; 95% confidence interval, 0.30-0.77; P = .002). The secondary end points were not significantly different between strategies. In a prespecified subgroup analysis of patients who had nadir hematocrit less than 23% or body surface area less than 1.40 m2, the oxygen delivery strategy seemed to be superior to the conventional strategy and the existence of quantitative interactions was suggested.ConclusionsAn oxygen delivery strategy for cardiopulmonary bypass management was superior to a conventional strategy with respect to preventing the development of acute kidney injury. 相似文献
98.
目的 研究人参-陈皮配伍治疗慢性阻塞性肺疾病(COPD)的主要活性成分和潜在的分子作用机制。方法 从TCMSP数据库中获取人参、陈皮的活性成分和潜在靶点,疾病靶点利用DrugBank、TTD、GeneCards数据库获取。“药物-化合物-靶点”互作网络可视化由Cytoscape3.6.1软件完成。通过绘制韦恩图得到人参、陈皮和COPD的共有靶点,运用Cytoscape平台获取共有靶点相互作用关系。通过DAVID数据库对共有靶点进行GO、KEGG富集分析。活性成分和关键靶点的分子对接由autodock vina实现,并采用体外抗炎活性实验进行验证。结果 从人参和陈皮中共筛选得到27个活性成分,800个疾病靶点,药物和疾病共有靶点70个。GO功能富集分析得到GO条目213个(P<0.01),KEGG通路富集筛选得到99条信号通路(P<0.01)。分子对接结果显示,甾醇类成分和黄酮类成分与关键靶点有较高的结合性。体外抗炎活性验证结果表明,川陈皮素、山奈酚、柚皮素、人参皂苷rh2能够减少炎症因子的分泌。结论 人参-陈皮配伍可通过多成分、多靶点和多通路调控炎症因子释放,达到治疗COPD的效果。 相似文献
99.
目的:研究胸段食管鳞癌术后复发模式,为术后放疗靶区勾画提供参考。方法:回顾分析我院2012年7月至2017年5月收治术后复发的81例胸段食管鳞癌患者的临床资料,参照AJCC第八版食管癌分期,将第1-8M站定义为上中纵隔淋巴结区,8Lo、9、15站定义为下纵隔淋巴结区,16-20站定义为上腹部淋巴结区。标记患者的复发部位,并分析局部复发、区域复发和远处转移的模式。结果:中位复发时间为12个月(2~103个月)。6例(7.4%)患者发生单纯局部复发,64例(79.0%)患者发生区域复发,11例(13.6%)患者发生远处转移。区域淋巴结复发中最高危的复发区域为上中纵隔淋巴引流区,此区域包含了82.8%的复发淋巴结,其次为上腹部淋巴结引流区(13.6%)。11例患者发生上腹部淋巴结复发,其中10(90.9%)例为胸下段,7例(63.6%)患者术后分期≥Ⅲ_(b)期。结论:胸段食管鳞癌术后复发模式以区域淋巴结复发为主,上中纵隔淋巴引流区为最高危复发区域,术后放疗靶区应重点包含。对于术后分期较晚的胸下段食管鳞癌,上腹部淋巴结引流区可能需要涵盖在放疗靶区内。吻合口、瘤床和下纵隔复发风险低,可不必常规涵盖在放疗靶区内。 相似文献
100.